NON-INVASIVE DIAGNOSIS AND FOLLOW-UP OF HYPERFERRITINAEMIA.

[1]  D. Melzer,et al.  Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK Biobank , 2019, British Medical Journal.

[2]  H. Saint-Jalmes,et al.  Non-invasive measurement of liver iron concentration using 3-Tesla magnetic resonance imaging: validation against biopsy , 2018, European Radiology.

[3]  F. Laine,et al.  Dysmetabolic iron overload syndrome (DIOS). , 2017, Presse medicale.

[4]  X. Causse,et al.  Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome: A randomized controlled study in 274 patients , 2017, Hepatology.

[5]  D. Crawford,et al.  Iron and non-alcoholic fatty liver disease , 2016, World journal of gastroenterology.

[6]  Y. Deugnier,et al.  Haemochromatosis , 2016, The Lancet.

[7]  D. Girelli,et al.  Identification of novel mutations in hemochromatosis genes by targeted next generation sequencing in Italian patients with unexplained iron overload , 2016, American journal of hematology.

[8]  P. Brissot,et al.  Non‐invasive assessment of liver fibrosis in C282Y homozygous HFE hemochromatosis , 2015, Liver international : official journal of the International Association for the Study of the Liver.

[9]  J. Viel,et al.  Decreased cardiovascular and extrahepatic cancer-related mortality in treated patients with mild HFE hemochromatosis. , 2015, Journal of hepatology.

[10]  Ju-Young Shin,et al.  Association of Serum Ferritin and the Development of Metabolic Syndrome in Middle-Aged Korean Men , 2012, Diabetes Care.

[11]  D. Vital-Durand,et al.  Sex and acquired cofactors determine phenotypes of ferroportin disease. , 2011, Gastroenterology.

[12]  T. Coates,et al.  MRI R2 and R2* mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients. , 2005, Blood.

[13]  E. Thomson,et al.  Hemochromatosis and iron-overload screening in a racially diverse population. , 2005, The New England journal of medicine.

[14]  V. Sébille,et al.  Non-invasive assessment of hepatic iron stores by MRI , 2004, The Lancet.

[15]  A. Guillygomarc’h,et al.  Circadian variations of transferrin saturation levels in iron‐overloaded patients: implications for the screening of C282Y‐linked haemochromatosis , 2003, British journal of haematology.

[16]  S. Chakrabarti,et al.  Noninvasive prediction of cirrhosis in C282Y‐linked hemochromatosis , 2002, Hepatology.

[17]  D. Girelli,et al.  Clinical, biochemical and molecular findings in a series of families with hereditary hyperferritinaemia–cataract syndrome , 2001, British journal of haematology.

[18]  G. Brittenham,et al.  Iron-chelating therapy and the treatment of thalassemia. , 1997, Blood.

[19]  Jia Ji-don.  EASL clinical practice guidelines for HFE hemochromatosis. , 2010, Journal of hepatology.